All News
Does Evusheld shield people living with rheumatic diseases?
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Read Article
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR
Richard Conway RichardPAConway ( View Tweet)
Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA?
Compared to central readers:
-Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs)
- Agreement w/ Academic rheumatologists was greater vs community rheumatologists
#ACR22 @RheumNow https://t.co/j2vFoKA3n0
Akhil Sood MD AkhilSoodMD ( View Tweet)
Study by Dr EPapachristodoulou on
features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers
Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern
👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash.
#ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N
sheila RHEUMarampa ( View Tweet)
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. Rachel Tate uptoTate ( View Tweet)
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22
https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF
Links:
Dr. John Cush RheumNow ( View Tweet)
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA
Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting.
https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO
Links:
Dr. John Cush RheumNow ( View Tweet)
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
Eric Dein ericdeinmd ( View Tweet)
Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G
Dr. Rachel Tate uptoTate ( View Tweet)
There's a lot of Scleroderma-like fibrosing skin disorders!
#ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
sheila RHEUMarampa ( View Tweet)
Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
Dr. Rachel Tate uptoTate ( View Tweet)
Excllent plenary, medication copay modifies treatment adherence in SLE
>$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%)
Easy to imagine that all our innovation cannot overcome access & barriers
Should be priority to fix
#ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy
Mike Putman EBRheum ( View Tweet)
Congenital ❤️ Block in Ro/La pregnancies
Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all on 1st echo
👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone
🔥Key messages🔥
🤰serial echo should start @ 16-18wk gestation
👶 early detection ⬆️ outcomes
#ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
Dr. Rachel Tate uptoTate ( View Tweet)
🖊️Eosinophilic fasciitis is not assoc. w/ RP
🖊️On biopsy, extends to SC fat and fascia
🖊️CS are 1st line tx; remission is the rule but takes a while so SLOWLY taper steroids
#ACR22 @Rheumnow #RheumTwitter https://t.co/Z26Gim9JUW
sheila RHEUMarampa ( View Tweet)
Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes. Abs 0952 #ACR22 @RheumNow https://t.co/LMfebb4GE1 https://t.co/0gYG245BXV
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE
@RheumNow #ACRBest https://t.co/uamJe05odq
Eric Dein ericdeinmd ( View Tweet)
Scleredema has an indolent course
Affected skin is doughy
Has 3 clinical subgrps:
💠classic adultorum - self-limited, +visceral involvement
💠blood dyscrasia
💠diabetes - visceral involvement is rare
#ACR22 @Rheumnow @rheumarhyme https://t.co/ZlQmCc1WYa
sheila RHEUMarampa ( View Tweet)